Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Blueprint Medicines Corporation - Common Stock (NQ:BPMC)

129.46 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Blueprint Medicines Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Where Blueprint Medicines Stands With Analysts ↗
Within the last quarter, Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings: 
Via Benzinga
News headline image
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Blueprint Medicines: Q2 Earnings Insights ↗
  Blueprint Medicines (NASDAQ:BPMC) reported its Q2 earnings results on Tuesday, August 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
A Preview Of Blueprint Medicines's Earnings ↗
Blueprint Medicines (NASDAQ:BPMC) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
3 Biotech Stock Picks From This Wedbush Analyst ↗
While the S&P 500 index peaked in January and has had a rough year, the biotech sector peaked last August. For the time being, both have found a short-term and possible long-term bottom in June. 
Via Benzinga
News headline image
4 Analysts Have This to Say About Blueprint Medicines ↗
Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Blueprint Medicines: Q1 Earnings Insights ↗
Blueprint Medicines (NASDAQ:BPMC) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Week In Review: Qiming Closes $3.2 Billion For China Healthcare And Technology Investments ↗
Qiming Venture Partners closed two new China healthcare and technology funds with $3.2 billion in fresh capital, both of them at their hard cap limits. The USD Fund VIII has $2.5 billion and the first... 
Via Talk Markets
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022 ↗
 
Via Benzinga
News headline image
This Analyst Thinks Blueprint Medicines' Non-Dilutive Funding 'Deflates M&A Speculation' ↗
 
Via Benzinga
News headline image
What 7 Analyst Ratings Have To Say About Blueprint Medicines ↗
Within the last quarter, Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 27, 2022 ↗
Upgrades 
Via Benzinga
News headline image
SVB Leerink Maintains Market Perform Rating for Blueprint Medicines: Here's What You Need To Know ↗
SVB Leerink has decided to maintain its Market Perform rating of Blueprint Medicines (NASDAQ:BPMC) and lower its price target from $82.00 to $60.00. Shares of Blueprint Medicines are trading down 8.32%... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Monday ↗
RBC Capital reduced Tesla, Inc. (NASDAQ: TSLA) price target from $1,175 to $1,100. Tesla shares fell 3.7% to $670.89 in pre-market trading. 
Via Benzinga
News headline image
91 Biggest Movers From Friday ↗
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto. 
Via Benzinga
News headline image
44 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Cogent Biosciences, Inc. (NASDAQ: COGT) shares jumped 77% to $8.79 after the company reported initial data from its ongoing Phase 2 APEX clinical trial. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 10, 2022 ↗
 
Via Benzinga
News headline image
What You Missed On Wall Street On Thursday ↗
Here are our top five lists with the news and calls moving stocks, that you better not have missed yesterday... 
Via Talk Markets
News headline image
Blueprint Stock Dives On The FDA's Tricky New Requirement For Its Leading Drug ↗
The FDA had a suggestion for Blueprint's midstage systemic mastocytosis test. 
Via Investor's Business Daily
News headline image
Bristol Myers Snaps Up Turning Point For $4.1 Billion In Cash — Is The Biotech Bear Dead? ↗
Bristol Myers is moving deeper into the targeted oncology space. 
Via Investor's Business Daily
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2022 ↗
Upgrades 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Wednesday ↗
Keybanc cut Ambarella, Inc. (NASDAQ: AMBA) price target from $160 to $120. Ambarella shares fell 5% to $81.00 in pre-market trading. 
Via Benzinga
News headline image
What 3 Analyst Ratings Have To Say About Blueprint Medicines ↗
Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Earnings Preview: Blueprint Medicines ↗
Blueprint Medicines (NASDAQ:BPMC) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
Blueprint Medicines Q1 2022 Earnings Conference Call On May 3, 2022 At 08:30 AM ET ↗
Blueprint Medicines (NASDAQ:BPMC) will host a conference call at 08:30 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
News headline image
Where Blueprint Medicines Stands With Analysts ↗
Over the past 3 months, 6 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
After Encouraging Data, Blueprint Medicines Plans Combination Cohort In Tagrisso Resistant Lung Cancer ↗
Blueprint Medicines Corp (NASDAQ: BPMC)  
Via Benzinga
News headline image
Wednesdays With Wedbush: 3 Smid-Cap Biotech Stock Picks ↗
Since the coronavirus pandemic began in early 2020, the FDA's plate has been full with reviews of COVID-19 vaccines and treatments. That has put the approval of many... 
Via Benzinga
News headline image
What 5 Analyst Ratings Have To Say About Blueprint Medicines ↗
Over the past 3 months, 5 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts are typically employed by large Wall Street banks and... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.